Preimplantation Genetic Haplotyping (PGH) is a clinical method of Preimplantation genetic diagnosis (PGD). PGH was first developed in 2006 at London's Guy's Hospital and greatly advances PGD by using DNA fingerprinting rather than identifying the actual genetic signature (such as point mutations).

Compared with previous techniques, PGH allows:

• the ability to screen male embryos.
• an increase the number of embryos that can be implanted when screening for X-linked disorders such as Duchenne muscular dystrophy and Becker's muscular dystrophy.
• offers a much greater number of individual tests.
• increased reliability.
• higher success rate.

It has already been used to screen for cystic fibrosis.

References

• Dr Pam Renwick et al (2006) Pamela J Renwick et al, (2006) Proof of principle and first cases using Preimplantation Genetic Haplotyping (PGH) - a paradigm shift for embryo diagnosis Reproductive Medicine On Line

External links

• PGH Press Release

Genetic disorders | Fertility medicine